Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Embecta Corp.

Embecta Corp. (EMBC) Stock Overview

Explore Embecta Corp.’s financial performance, market position, analyst ratings, and future outlook.

EMBC●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$5.23
$0.24(4.39%)
U.S. Market opens in 62h 58m

Embecta Corp. (EMBC)

Meyka AI Score

Z

Key Financials

Market Cap310.3M
P/E Ratio3.50
EPS (TTM)$2.60
ROE-0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$6.39
3 Months$5.16
1 Year Target$5.77

EMBC Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Embecta Corp. (NASDAQ: EMBC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Embecta Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EMBC on the NASDAQ shows an RSI of 69.30, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.77 for the NASDAQ listing.

Key metrics behind Embecta Corp.'s NASDAQ-traded stock include a P/E ratio of 3.50 and a market capitalization of 310.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EMBC on the NASDAQ.

Price Performance (NASDAQ: EMBC)

1-Day Change
-4.39%
5-Day Change
1.36%
1-Month Change
55.19%
3-Month Change
57.53%
6-Month Change
-51.26%
Year-to-Date (YTD) Change
-55.98%
1-Year Change
-62.18%
3-Year Change
-69.54%
5-Year Change
-88.87%
All-Time (Max) Change
-88.87%

Contact Information

https://www.embecta.com
201 847 6880
300 Kimball Drive, Parsippany, NJ, 07054

Company Facts

18,500 Employees
IPO DateMar 22, 2022
CountryUS
Actively Trading

Frequently Asked Questions